Filtered By:
Specialty: International Medicine & Public Health
Condition: Atrial Fibrillation
Drug: Lovenox
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Health Care Cost In Patients Undergoing Electrical Cardioversion: An Analysis From The Edoxaban Versus Warfarin In Subjects Undergoing Cardioversion of Atrial Fibrillation (ENSURE-AF) Study
Electrical cardioversion (EC) restores and maintains sinus rhythm in atrial fibrillation (AF) patients. Edoxaban, a direct oral anticoagulant indicated for prevention of stroke or systemic embolic event (SEE) in patients with non-valvular atrial fibrillation (NVAF) was compared with enoxaparin –warfarin in patients undergoing EC in ENSURE-AF (NCT 02072434) study, a phase 3b open-label, multi-national open-label trial comparing edoxaban with enoxaparin/warfarin followed by warfarin alone in 2,199 NVAF patients.
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: J Rodriguez Barrrios, A Goette, J Kwong, MD Ezekowitz, M Banach, SP Hjortsh øj, D Zamoryakhin, G Lip Source Type: research
